Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Thursday; AppLovin to Advance, Sandisk to Decline

Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Thursday; AppLovin to Advance, Sandisk to Decline

MT newswireMT newswire2026/11/05 10:39
06:39 AM EST, 11/05/2026 (MT Newswires) -- The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Thursday's opening bell. AppLovin (APP) rose 18% in pre-bell activity, after closing Wednesday with a 10.7% increase. AppLovin reported higher Q3 earnings and revenue. Apple (AAPL) was 0.6% higher pre-bell, following a 5.3% rise at Wednesday's close. Microsoft (MSFT) was up 0.2% in premarket hours, after a 6.7% increase from the previous session. SanDisk (SNDK) was 3.5% lower premarket, following a 7.9% fall from Wednesday's session. Advanced Micro Devices (AMD) fell 3% pre-bell, swinging from a 1% increase at Wednesday's close. Micron Technology (MU) declined by 2.5% in premarket hours, after a 7% fall from the previous session. Tesla (TSLA) was down 2% hours before the market open, after closing Wednesday with a 3.3% fall. Nvidia (NVDA) was 0.9% lower premarket, following a 3.2% decline at Wednesday's close.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss